Skip to main content

Table 1 Characteristics of the total COLIBRI population at the time of data extraction, and comparison between patients with or without complete data

From: Are there specific clinical characteristics associated with physician’s treatment choices in COPD?

Characteristics

Total

Complete data

Incomplete data

Overall P Value

N

Mean ± SD /n (%)

N

Mean ± SD /n (%)

N

Mean ± SD /n (%)

Age, in year

4140

65.9 ± 9.9

1171

65.2 ± 8.4

2969

66.1 ± 10.4

0.005*

Gender, male, n(%)

4146

2910 (70.2)

1171

811 (69.3)

2975

2099 (70.6)

0,411

BMI, kg/m2

3866

25.8 ± 5.9

1171

26.1 ± 5.9

2695

25.6 ± 6.0

0.044*

COPD GOLD stages, n(%)

3730

 

1171

 

2559

  

 GOLD I

 

745 (20.0)

 

241 (20.6)

 

504 (19.7)

0,53

 GOLD II

 

1594 (42.7)

 

501 (42.8)

 

1093 (42.7)

0,967

 GOLD III

 

883 (23.7)

 

294 (25.1)

 

589 (23.0)

0,163

 GOLD IV

 

508 (13.6)

 

135 (11.5)

 

373 (14.6)

0.012*

VEMS, % predicted

3730

59.4 ± 22.8

1171

59.9 ± 22.1

2559

59.2 ± 23.0

0,293

CVF, % predicted

3670

85.1 ± 22.7

1171

87.7 ± 23.4

2499

83.9 ± 22.2

< 0.001*

Active smoker, n(%)

3829

1321 (34.5)

1158

449 (38.8)

2671

872 (32.6)

< 0.001*

Cigarette smoker pack-years

3614

43.3 ± 24.4

1132

45.6 ± 22.8

2482

42.3 ± 25.0

< 0.001*

mMRC Score

3231

1.9 ± 1.2

1171

1.7 ± 1.1

2060

1.9 ± 1.2

< 0.001*

mMRC Score ≥ 2, n (%)

3231

1839 (56.9)

1171

627 (53.5)

2060

1212 (58.8)

0.004*

HAD Score

1621

12.3 ± 7.2

1171

12.3 ± 7.1

450

12.5 ± 7.5

0,877

CAT score

1863

16.7 ± 7.7

1171

16.8 ± 7.7

692

16.6 ± 7.9

0,545

DIRECT score

1803

12.1 ± 7.7

1171

11.8 ± 7.6

632

12.6 ± 7.9

0,05

Treatment category

3642

 

1171

 

2471

  

 A

 

676 (18.6)

 

214 (18.3)

 

462 (18.7)

0,76

 B

 

620 (17.0)

 

223 (19.0)

 

397 (16.1)

0.026*

 C

 

534 (14.7)

 

217 (18.5)

 

317 (12.8)

< 0.001*

 D

 

498 (13.7)

 

132 (11.3)

 

366 (14.8)

0.004*

 E

 

1314 (36.1)

 

385 (32.9)

 

929 (37.6)

0.006*

LTOT, n(%)

4157

768 (18.5)

1171

170 (14.5)

2986

598 (20.0)

< 0.001*

Long-term NIV, n(%)

4157

246 (5.9)

1171

83 (7.1)

2986

163 (5.5)

0.045*

Long-term CPAP, n(%)

4157

319 (7.7)

1171

68 (5.8)

2986

251 (8.4)

0.005*

Exacerbations last year (≥1 severes or ≥ 2 moderate), n (%)

3409

1251 (36.7)

1171

389 (33.2)

2238

862 (38.5)

0.002*

Cardio-vascular comorbidity

4157

2484 (59.8)

1171

690 (58.9)

2986

1794 (60.1)

0,494

  1. Values were mean ± SD unless otherwise specified. * highlight statistically significant differences
  2. Comparisons by Chi-square analysis (category variables) or T- test (normally distributed continuous variables) or Mann Whitney U test (not normally distributed continuous variables)
  3. A category: no COPD treatment or short-acting bronchodilator(s) (SABA and/or SAMA) only; B category: LABA OR LAMA; C category: LABA+LAMA; D category: LABA OR LAMA + ICS; E category: LABA+LAMA+ICS
  4. HAD hospital anxiety-depression scale, mMRC modified medical research council dyspnea scale, CAT COPD assessment test, DIRECT Disability Related to COPD Tool, LTOT long-term oxygen therapy, NIV non-invasive ventilation, CPAP continuous positive airway pressure
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us